Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment

Author： Sun Junzhong   Xu Yin   Song Santai   Wu Zuze   Duan Haifeng  

Publisher： Informa Healthcare

ISSN： 1388-0209

Source： Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol.49, Iss.11, 2011-11, pp. : 1167-1172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

By Hare Jennifer I.   Moase Elaine H.   Allen Theresa M.  

Journal of Drug Targeting, Vol. 21, Iss. 1, 2013-01 ,pp. : 87-96

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel and docetaxel in the treatment of breast cancer

By Saloustros Emmanouel   Mavroudis Dimitris   Georgoulias Vassilis  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2603-2616

Informa Healthcare

Access to resources Recommend Favorite

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Preoperative trastuzumab, docetaxel and carboplatin therapy is effective for HER2-positive breast cancer

By  

Inpharma, Vol. 1, Iss. 1592, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Current and Future Treatment Strategies

By Engel Ryan H.   Kaklamani Virginia G.  

Drugs, Vol. 67, Iss. 9, 2007-01 ,pp. : 1329-1341

Adis International

Access to resources Recommend Favorite